Phase I clinical evaluation of <sup>99m</sup>Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer.
Journal Information
Full Title: Theranostics
Abbreviation: Theranostics
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Diagnostic Imaging
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Competing Interests: Maryam Oroujeni, Annika Loftenius, Fredrik Y. Frejd are employees of Affibody AB. Anna Orlova and Vladimir Tolmachev are members of Technical advisory board of Affibody AB."
"This research was financially supported by the Swedish Cancer Society (CAN 21 1485 Pj) and the Ministry of Science and Higher Education of the Russian Federation (075-15-2019-1925)."
"This was a prospective, open-label, nonrandomized phase I diagnostic study in patients with untreated primary breast cancer (ClinicalTrials.gov Identifier: NCT05203497). The study protocol was approved by the Scientific Council of Cancer Research Institute and Board of Medical Ethics, Tomsk National Research Medical Center of the Russian Academy of Sciences (protocol №13, 09.11.2021), and all patients signed a written informed consent form."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025